Skip to content
The Policy Vault
Methodology
Why
Contact
Coverage
/
Medica
/
sunitinib malate
/
Meningioma
← Back
sunitinib malate — Medica
Meningioma
Initial criteria
age ≥ 18 years
Patient has recurrent or progressive disease
Approval duration
1 year